Five Potential Blockbuster Oncology Approvals To Look Out For In 2023

06 Sep 2022

• By Ayisha Sharma

With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.

Piggy Money — These Pipeline Drugs Could Exceed $1bn In Sales • Source: Shutterstock

One of three CD20 X CD3 bispecific antibody candidates striving for a 2023 thumbs up in late-stage diffuse large B-cell lymphoma (DLBCL), Genmab A/S and partner AbbVie Inc.’s epcoritamab is set to be filed in the EU later this year. The firms are also preparing for a US filing in large B-cell lymphoma.

While chimeric antigen receptor (CAR) T-cell drugs such as Kite Pharma’s Yescarta (axicabtagene ciloleucel) have recently won approval in...